We’ve combined our tools and data to help you accelerate your drug development program
For all of our products we use a suite of human genetic tools to allow you to attract investment and make critical pipeline decisions.
Target Intelligence Reports
This product helps you understand the human genetic evidence supporting a specific drug target for a disease indication.
This is useful for biotech, pharma and their investors who want to know if human genetic evidence supports their drug development program.
Disease Intelligence Reports
This product allows you to understand which targets
in the human genome have the best human genetic evidence for a specific disease.
This is the ideal product for early-stage drug developers who understand that drug development programs based on human genetics are more likely to succeed to market.
Our Human Genetic Tools
Genome-Wide Association Studies
These findings have a high sensitivity to identify tractable drug targets.
Whole Exome Sequencing
Whole exome sequencing can unambiguously identify high-yield drug targets and the required direction of effect for a pharmacological intervention.
PRIMEx
PRIMEx is our machine-learning algorithm that quantifies the probability that a specific drug target is causal for a disease of interest using large-scale datasets from GWAS.
Mendelian Randomization
Drug development programs with support from Mendelian randomization evidence have a strong track-record of reaching the market. We use Mendelian randomization to assess whether a specific target is causal for the disease of interest.
Mendelian Genetics
Heritable rare disease is often caused by highly penetrant Mendelian mutations. We use these findings to identify and validate drug targets often pointing to the direction of effect for the required pharmaceutical intervention.